CLOs on the Move

Image 2 Print

www.laminatetops.com

 
Image 2 Print is a San Diego, CA-based company in the Business Services sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

GoToCollegeFairs

Providing trusted technology to college fairs and higher ed for over 15 years. Real time leads, secure student data.

Pro Fitness

Pro Fitness is a Prescott Valley, AZ-based company in the Business Services sector.

Community Council Montgomery

Community Council Montgomery is a Montgomery, AL-based company in the Business Services sector.

TekReplay

TekReplay is a leader in buying and selling high quality mobile devices. Since 2008, our company has served thousands of happy customers and were proud to have delivered the highest level of customer service possible. We take great pride in our dedicated customer service and overall quality of our products. We guarantee that you will be satisfied with your purchase. We specialize in selling quality refurbished Macs, iPhones, and iPads at competitive prices. If you have any questions please feel free to contact us at sales@tekreplay.com

Skye Bioscience Inc.

Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.